The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Functional cure of hepatitis B is defined as sustained undetectable circulating HBsAg and
HBV DNA after a finite course of treatment. Barriers to HBV cure include the reservoirs for …

Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Chronic hepatitis B virus (HBV) infection is a global public health challenge on the same
scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE …

Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …

Liver cancer has the fourth highest mortality rate of all cancers worldwide, with
hepatocellular carcinoma (HCC) being the most prevalent subtype. Despite great advances …

Representatives from academia, industry, regulatory agencies, and patient groups
convened in March 2019 with the primary goal of developing agreement on chronic hepatitis …

Chronic hepatitis B virus (HBV) infection is one of the high-risk factors for human HCC.
Despite the integration of virus DNA and the oncoprotein HBx, chronic necroinflammation …

Hepatocellular carcinoma (HCC) is one of the world's deadliest and fastest-growing tumors,
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …